Bg pattern

CINFATUSINA 3.54 mg/ml ORAL SUSPENSION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use CINFATUSINA 3.54 mg/ml ORAL SUSPENSION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show translation

Introducción

Prospecto: información para el usuario

cinfatusina 3,54 mg/ml suspensión oral

Cloperastina fendizoato

Lea todo el prospecto detenidamente antes de empezar a tomar este medicamento, porque contiene información importante para usted.

Siga exactamente las instrucciones de administración del medicamento contenidas en este prospecto o las indicadas por su médico o farmacéutico.

  • Conserve este prospecto, ya que puede tener que volver a leerlo.
  • Si necesita consejo o más información, consulte a su farmacéutico.
  • Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.
  • Debe consultar a un médico si empeora o si no mejora después de 7 días.

Contenido del prospecto

  1. Qué es cinfatusina y para qué se utiliza.
  2. Qué necesita saber antes de empezar a tomar cinfatusina.
  3. Cómo tomar cinfatusina.
  4. Posibles efectos adversos.
  5. Conservación de cinfatusina.
  6. Contenido del envase e información adicional.

1. Qué es cinfatusina y para qué se utiliza

La cloperastina, principio activo de este medicamento, es un antitusivo que inhibe el reflejo de la tos. Cinfatusina es un medicamento indicado para el tratamiento de las formas improductivas de tos, como tos irritativa o tos nerviosa para adultos y niños a partir de 2 años.

Debe consultar a un médico si empeora o si no mejora después de 7 días de tratamiento.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. Qué necesita saber antes de empezar a tomar cinfatusina

No tome cinfatusina

  • Si es alérgico a la cloperastina fendizoato o a alguno de los demás componentes de este medicamento (incluidos en la sección 6).
  • Si es alérgico a los medicamentos para la alergia (antihistamínicos).
  • Si está tomando medicamentos para el tratamiento de la depresión.
  • Si está embarazada o cree estarlo o si se encuentra en periodo de lactancia.
  • No administrar cinfatusina a niños menores de 2 años.

Advertencias y precauciones

Consulte a su médico o farmacéutico antes de empezar a tomar cinfatusina:

  • Si tiene la presión intraocular alta.
  • Si le han dicho que tiene hipertrofia de la próstata.
  • Si presenta dificultad para orinar.
  • Si es hipertenso.
  • Si tiene problemas de corazón.
  • Si tiene una enfermedad degenerativa muscular llamada miastenia grave.
  • Si presenta algún tipo de obstrucción gástrica o intestinal, incluyendo úlcera.
  • Si presenta tos crónica por ser fumador, por tener problemas pulmonares o asma.
  • Si la tos persiste después de 7 días de tratamiento.

Niños

Los niños menores de 2 años no pueden tomar este medicamento, está contraindicado.

Otros medicamentos y cinfatusina

Informe a su médico o farmacéutico si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.

Cinfatusina puede interaccionar con otros medicamentos tales como:

  • Medicamentos para ayudarle a dormir (sedantes, analgésicos opioides, barbitúricos, hipnóticos o benzodiacepinas).
  • Medicamentos para la depresión y medicamentos para el tratamiento del Parkinson porque pueden potenciar los efectos adversos de este medicamento.
  • Medicamentos expectorantes y mucolíticos utilizados para eliminar el exceso de mocos y flemas, porque al tomar al mismo tiempo que un medicamento para la tos como es cinfatusina, se puede impedir la eliminación del exceso de moco y producir ahogo.

Toma de cinfatusina con alimentos, bebidas y alcohol

Durante el tratamiento con Cinfatusina no se debe de tomar alcohol ya que puede incrementar los efectos del alcohol.

La toma de este medicamento con alimentos y bebidas no afecta a la eficacia del mismo.

Embarazo y lactancia

Si está embarazada o en periodo de lactancia, cree que podría estar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de utilizar este medicamento.

Está contraindicado en embarazo y lactancia.

Conducción y uso de máquinas

Cinfatusina puede producir somnolencia a las dosis habituales. Si así fuera, absténgase de conducir y manejar maquinaria peligrosa.

Cinfatusina contiene parahidroxibenzoato de metilo y parahidroxibenzoato de propilo.

Puede producir reacciones alérgicas (posiblemente retardadas) porque contiene parahidroxibenzoato de metilo (E-218) y parahidroxibenzoato de propilo (E-216).

Cinfatusina contiene sodio.

Este medicamento contiene menos de 23 mg de sodio (1 mmol) por ml; esto es, esencialmente “exento de sodio”.

3. Cómo tomar cinfatusina

Siga exactamente las instrucciones de administración del medicamento contenidas en este prospecto o las indicadas por su médico o farmacéutico. En caso de duda, pregunte a su médico o farmacéutico.

La dosis recomendada es:

En adultos y adolescentes mayores de 12 años: 10 ml, 3 veces al día.

En niños:Entre 7 y 12 años: 5 ml, 2 veces al día.

Entre 5 y 6 años: 3 ml, 2 veces al día.

Entre 2 y 4 años: 2 ml, 2 veces al día.

Cinfatusina está contraindicado en niños menores de 2 años.

Agitar el frasco antes de usarlo.

Este medicamento se toma por vía oral.

Para la correcta administración utilizar el vasito o jeringa dosificadora incluido en el envase.

Si toma más cinfatusina del que debe

Los síntomas de la sobredosis son: excitación y dificultad para respirar.

En caso de sobredosis o ingestión accidental consulte inmediatamente a su médico o farmacéutico o llame al Servicio de Información Toxicológica, teléfono 91 562 04 20, indicando el medicamento y la cantidad ingerida.

Si olvidó tomar cinfatusina

No tome una dosis doble para compensar las dosis olvidadas.

Este tratamiento es sintomático si no tiene tos no lo tome y si la vuelve a tener, tome el medicamento como se indica en la sección 3. Cómo tomar Cinfatusina.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Posibles efectos adversos

Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.

Los efectos adversos que más se pueden producir aunque son poco frecuentes son: somnolencia y sequedad de boca.

Los efectos adversos que se pueden producir son:

Poco frecuentes (pueden afectar hasta 1 de cada 100 pacientes): somnolencia, sequedad de boca (a altas dosis) alteraciones del movimiento, temblores y mareos.

Muy raros (pueden afectar hasta 1 de cada 10.000 pacientes): reacción alérgica, urticaria.

Comunicación de efectos adversos

Si experimenta cualquier tipo de efecto adverso, consulte a su médico o farmacéutico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través del Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano: https://www.notificaram.es. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.

5. Conservación de cinfatusina

Mantener este medicamento fuera de la vista y del alcance de los niños.

Este medicamento no requiere condiciones especiales de conservación.

No utilice este medicamento después de la fecha de caducidad que aparece en el envase después de CAD. La fecha de caducidad es el último día del mes que se indica.

No utilice cinfatusina después de dieciocho meses de la fecha de apertura del envase.

Los medicamentos no se deben tirar por los desagües ni a la basura. Deposite los envases y los medicamentos que no necesita en el Punto SIGRE de la farmacia. En caso de duda pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que no necesita. De esta forma ayudará a proteger el medio ambiente.

6. Contenido del envase e información adicional

Composición de cinfatusina

El principio activo de cinfatusina es cloperastina fendizoato. Cada ml de suspensión oral contiene 3,54 mg de cloperastina fendizoato (equivalente a 2 mg de cloperastina hidrocloruro).

Los demás componentes son: Parahidroxibenzoato de metilo (E-218), Parahidroxibenzoato de propilo (E-216), Goma Xantán (E-415), Glicerol (E-422), Carbómeros (Carbopol 974 P), Estearato de macrogol, Aroma de plátano, Sacarina sódica (E-954) y Agua purificada.

Aspecto del producto y contenido del envase

Se presenta en forma de suspensión oral. Cada envase contiene 120 ml o 200 ml de suspensión oral y un vaso dosificador con medidas de 2,5 a 15 ml, así como una jeringa dosificadora con medidas de 0,25 ml a 5 ml.

Titular de la autorización de comercialización y responsable de la fabricación

Laboratorios Cinfa, S.A

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - España

Fecha de la última revisión de este prospecto:Febrero 2021

La información detallada y actualizada de este medicamento está disponible en la página web de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) http://www.aemps.gob.es/

Online doctors for CINFATUSINA 3.54 mg/ml ORAL SUSPENSION

Discuss questions about CINFATUSINA 3.54 mg/ml ORAL SUSPENSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for CINFATUSINA 3.54 mg/ml ORAL SUSPENSION?
CINFATUSINA 3.54 mg/ml ORAL SUSPENSION does not require a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in CINFATUSINA 3.54 mg/ml ORAL SUSPENSION?
The active ingredient in CINFATUSINA 3.54 mg/ml ORAL SUSPENSION is cloperastine. This information helps identify medicines with the same composition but different brand names.
Who manufactures CINFATUSINA 3.54 mg/ml ORAL SUSPENSION?
CINFATUSINA 3.54 mg/ml ORAL SUSPENSION is manufactured by Laboratorios Cinfa S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of CINFATUSINA 3.54 mg/ml ORAL SUSPENSION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether CINFATUSINA 3.54 mg/ml ORAL SUSPENSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to CINFATUSINA 3.54 mg/ml ORAL SUSPENSION?
Other medicines with the same active substance (cloperastine) include CLOPERASTINE KERN PHARMA 3.54 mg/ml SYRUP, CLOPERASTINE NORMON 3.54 mg/ml ORAL SUSPENSION, FLUTOX 10 mg FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media